 Cost to avoid 1 relapse and the Number Needed tot Treat (NNT) to avoid 1 relapse with each therapy versus its trial comparators were calculated.
 Efficacy inputs were previously published Annualized Relapse Rates (ARR) from trials (1) (2) (3) (4) (5) (6) (7) (8) . When subgroup analyses from clinical trials were available, they were used to differentiate efficiency in different patient subgroups or to approximate populations to treatment indication.
 Economic inputs included drug and relapse costs. Drug annual costs were calculated according to Spanish list prices (9) . Costs of mild, moderate and severe relapses were recently estimated at 322€, 1.027€ and 3.576€, respectively (10); an average cost of 1.641,67€ was applied to this analysis.
 Costs to avoid 1 relapse were calculated as the quotient between the annual incremental costs and the incremental relapse rates (relapse savings) from each drug vs its comparator.
 NNTs were calculated based on incremental effectiveness, and represents the number of patients needed to be treated to avoid one event.
 Clinical and economic inputs are shown in Figure 1 .
RESULTS

CONCLUSIONS
 New therapies (DMF, teriflunomide and alemtuzumab) were related to higher costs and higher NNT to avoid 1 relapse compared to fingolimod and natalizumab.
 Drug comparator and patient subgroups aimed to be important drivers to explain relative efficiencies.
 These results should be confirmed through head-to-head comparisons.  NNTs and incremental costs to avoid 1 relapse were generally correlated, with higher NNTs being observed in drugs with lower efficiency ratios.
